Loading...

Table of Content

    04 August 2014, Volume 41 Issue 7 Previous Issue    Next Issue
    For Selected: Toggle Thumbnails
    Research progress in association between the Kruppellike factor 9 and tumor development
    SHEN Peng-Liang, SHI Guo-Wei
    2014, 41 (7):  481-484.  doi: 10.3760/cma.j.issn.1673422X.2014.07.001
    Abstract ( 1066 )   PDF (804KB) ( 1711 )   Save
    KLF9 (Kruppellike factor 9) is the transcription factor that can bind GCrich sites through three C2H2type zinc fingers and can regulate diverse biological processes, including cell proliferation, apoptosis and the development of the organ. KLF9 is downregulated in some tumor specimens and tumorous cell lines relative to the normal samples and cell lines and plays an important role in the growth of cancer cells. Similar with the other KLF numbers, KLF9 could affect the development of tumors, especially for the endocrinerelated cancers through multiple signaling pathways and interventions with other proteins.
    Related Articles | Metrics
    EML4ALK fusion gene in tumor
    GUO Yi-Nan, YUE Wen-Tao
    2014, 41 (7):  484-487.  doi: 10.3760/cma.j.issn.1673422X.2014.07.002
    Abstract ( 504 )   PDF (726KB) ( 1400 )   Save
    EML4ALK fusion gene is one of the novel targets in the therapy of lung cancer, which can be detected in several kinds of tumors. A specific ALK inhibitor has been shown to exert antitumor effects in nonsmall cell lung cancer with the EML4ALK fusion gene. Correlative study between EML4ALK gene fusion and EGFRKras mutations might cast new insight on the tumor target therapy.
    Related Articles | Metrics
    Advances in the research on epigenetic regulation factors—SNF5 and EZH2 in the carcinogenesis and progress of different tumors
    WU Shao-Hua, DAN Li-Zhu, WANG Hua-Qing
    2014, 41 (7):  488-492.  doi: 10.3760/cma.j.issn.1673422X.2014.07.003
    Abstract ( 540 )   PDF (738KB) ( 1643 )   Save
    Epigenetics refers to heritable alterations in gene expression that do not involve the DNA coding sequence itself. Epigenetic regulation plays an important role in gene expression, DNA replication, reparation and reconstitution. Thus, the abnormity of epigenetic regulation may lead to different diseases, especially cancer. SNF5, which can suppress tumor significantly, is one of the core components of SWI/SNF chromosome remodeling complexes. EZH2, a histone methyltransferase, is closely and complicatedly related to cancer and has significant effect on tumorigenesis. There are many studies reporting the effects of epigenetic regulation factors—SNF5 and EZH2 on different tumors as well as the interrelation at present. In the present paper, the advances in the research on these two epigenetic regulation factors in the carcinogenesis are reviewed.
    Related Articles | Metrics
    Nucleobindin 2 and its role in tumorigenesis and progression
    YANG Yi, MAO Shan-Hua, LI Zhen-Yang, GU Xiao-Dong, XIANG Jian-Bin, CHEN Zong-You
    2014, 41 (7):  492-494.  doi: 10.3760/cma.j.issn.1673422X.2014.07.004
    Abstract ( 484 )   PDF (722KB) ( 1205 )   Save
    Nucleobindin 2 protein(NUCB2) is a newly discovered neuropeptide precursor protein, which has a comprehensive cytology function and is expressed in the hypothalamus nucleus and many peripheral tissues. There aren′t many studies about its signaling pathway, where neuroendocrine regulation, cell survival growth, tumor suppressor, cytokine secretion were found to involve in it. Besides, it has also been confirmed that breast cancer, lung cancer, ovarian cancer and prostate cancer are closely related to NUCB2. Therefore, several downstream pathways of NUCB2 may be related to the formation and progression of tumor. Further studies are still needed to clarify the signal pathways of NUCB2 to provide a reliable basis for clinical cancer prevention.
    Related Articles | Metrics
    The progression of chimeric antigen receptor modified T cells in malignant tumor
    ZHANG Shao-Hua, BI Jing-Wang
    2014, 41 (7):  495-499.  doi: 10.3760/cma.j.issn.1673422X.2014.07.005
    Abstract ( 449 )   PDF (737KB) ( 2081 )   Save
    Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)engineered T cells. CAR combine the variable regions of a specific monoclonal antibody (scFv) with the CD3ζ endodomain.The extracellular domain of CARengineered T cells directly dock to the tumorassociated antigen (TAA). When T cells bind to target antigens,they mediated redirected cytotoxicity and secrete a series of cytokines such as Perforin, Granzyme, Interferonγ (IFNγ)and Tumor necrosis factorα (TNFα),  which would eventually lead to the necrosis of tumor cells. Although the antitumor response of the CARengineered T cells is considered as successful and surprising, it should be noted that some safety issues have been observed in other several basic researches and clinical trials. This overview focuses upon the utility and safety of the CARengineered T cells.
    Related Articles | Metrics
    Research progress of kinetochore protein CENPF in malignant tumor
    ZHENG Jin, LIN Ying-Cheng
    2014, 41 (7):  500-502.  doi: 10.3760/cma.j.issn.1673422X.2014.07.006
    Abstract ( 510 )   PDF (716KB) ( 1512 )   Save
    CENPF is a cellcycle dependent kinetochore protein, whose expression and localization patterns are regulated in a cell cycledependent manner. CENPF plays an important role in the development and progress of malignant tumor. The expression of CENPF is upregulated in many tumors. It serves as an important marker in cell proliferation. Studies have demonstrated that CENPF is involved in tumor genesis, progress, invasiveness, relapse and prognosis. CENPF might be a valuable prognostic marker and potential therapy target in cancer treatment.
    Related Articles | Metrics
    NFκB in neoplasms radiotherapy
    DU Zheng-Yun, XIAO Bao-Rong, DI Xi-Ju
    2014, 41 (7):  503-507.  doi: 10.3760/cma.j.issn.1673422X.2014.07.007
    Abstract ( 337 )   PDF (763KB) ( 1242 )   Save
    Nuclear factor κB (NFκB) is an important transcription factor in mammalian cells. As a multifunctional factor, NFκB is involved in a variety of physiological and pathological processes such as immunity and inflammation . At the molecular and cellular level, NFκB regulates initiation and progression of neoplasms. NFκB also plays an important role in cell proliferation and apoptosis of neoplasms. Radiotherapy is one of the most important methods in tumor treatment .In recent years, a number of studies discovered that NFκB is critical in the development of resistance of tumor cells to radiotherapy, which results in poor prognosis. We can use NFκB as a biomarker in predicting outcomes of anticancer treatment or as prognostic indicators in patients who are with tumors. So we can find different potential inhibitors aimed at NFκB and its signal pathway in order to improve the efficacy of radiotherapy. In the present study, the correlation of NFκB molecules with radiotherapy of neoplasms is reviewed.
    Related Articles | Metrics
    PET hypoxia imaging and progress of enhancing radiosensitivity in hypoxic tumor
    LUO Zheng, ZHU Hua, LIN Xin-Feng, XIAO Shao-Wen, YANG Zhi
    2014, 41 (7):  507-511. 
    Abstract ( 381 )   PDF (737KB) ( 1460 )   Save
    Hypoxia is one of the most important factors influencing cancer therapy and clinical prognosis. With positron emission tomography (PET) widely adopted in clinical practice, the development and application of PET hypoxia imaging agents has been much popular in the field currently. PET hypoxia imaging can detect tumor hypoxia region noninvasively, which has important significance for optimizing cancer treatment decisions and improving the prognosis of cancer.
    Related Articles | Metrics
    Research progress of cell division cycle 25 homolog C and tumor  radiosensitivity
    YIN Ya-Chao, LI Duo-Jie
    2014, 41 (7):  511-514.  doi: 10.3760/cma.j.issn.1673422X.2014.07.009
    Abstract ( 561 )   PDF (731KB) ( 1170 )   Save
    As one of the Cdc25 phosphatase family members, Cdc25C plays an important role in regulating mitosis of eukaryotic cells.In eukaryotic cells, CDK1cell cycle protein B (CyclinB) compound mainly control the process of G2M. The activity of Cdc25C is the key in cell cycle into M phase. It activates CDK1cyclinB complexes to promote cells from G2 to M phase . Improving Cdc25C activity can promote the G2M phase transition, and remove the G2M phase retardation induced by ionizing radiation, preventing the damaged DNA from repaired into the phase of cell division, resulting in cell death caused by excessive cell proliferation, thus enhance radiosensitivity.
    Related Articles | Metrics
    The mechanism research of EGFRTKI resistance
    XIONG Xing-An, WANG Meng, CAI Zhi-Qiang
    2014, 41 (7):  515-517.  doi: 10.3760/cma.j.issn.1673422X.2014.07.010
    Abstract ( 500 )   PDF (722KB) ( 1324 )   Save
    Epidermal growth factor receptor  tyrosine kinase inhibitor (EGFRTKI) resistance in nonsmall cell lung cancer(NSCLC) has become more and more common, which includes primary and secondary resistance. The primary resistance is mainly related with EGFR gene mutation, and the secondary resistant is mainly related with T790M, MET and other genes.
    Related Articles | Metrics
    The research on inflammatory reaction and differential expression of microRNAs in lung caner
    JIN Dong-Xu, ZHAO Guang-Qiang, HUANG Yun-Chao, LI Hu
    2014, 41 (7):  518-520.  doi: 10.3760/cma.j.issn.1673422X.2014.07.011
    Abstract ( 462 )   PDF (721KB) ( 1344 )   Save
    MicroRNA is a type of singlestranded noncoding RNA,directly bonding to the complementary target gene mRNA. That leads to the inhibition of mRNA translation of the target molecule in order to reduce expression of the target gene. MicroRNAs are not only involved in the regulation of inflammatory reaction, but also play important roles in the formation of neoplasm. The researches showing that the inflammatory reaction interacting with miRNAs results in the differential expressions of microRNAs in lung cancer have been widespreadly concerned. Along with the deepening of the research on the mechanisms of inflammatory reaction and differential expression of microRNAs, it will provide new strategies for the prevention, diagnosis and treatment of lung cancer.
    Related Articles | Metrics
    Advance of targeted therapy for gastric cancer
    XUE Ke-Wei, LI Gui-Xin, WANG Gong-Ai, JIANG Yu
    2014, 41 (7):  520-522.  doi: 10.3760/cma.j.issn.1673422X.2014.07.012
    Abstract ( 456 )   PDF (724KB) ( 1368 )   Save
    In recent years many targeted agents treating gastric cancer have been evaluated in clinical studies. Trastuzumab, an antiHER2 monoclonal antibody, has shown activity against HER2positive gastric cancer and become the first targeted agent approved in gastric cancer. Drugs targeting epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, bring survival benefit to patients with gastric cancer. Additionally, vascular endothelial growth factor inhibitors are also under investigation. Other targeted agents are in preclinical or early clinical development, such as mTOR inhibitors and cMET inhibitors.
    Related Articles | Metrics
    Progress in research on animal models of liver cancer
    HUANG Jia-Fei, ZHOU Hong-Yuan, ZHANG Ti
    2014, 41 (7):  523-525.  doi: 10.3760/cma.j.issn.1673422X.2014.07.013
    Abstract ( 437 )   PDF (717KB) ( 1610 )   Save
    As a result, establishing animal models of liver cancer is of high value. There are two parts of the establishment of animal models—the selection of laboratory animals and the source of tumors.  The animal models could be classified into different patterns due to difference sources of tumor, and these different patterns possess distinctive characters and limitations. The ideally animal models should satisfy the general requirements of biological habits, biochemical properties, and pathological features which are similar with human hepatocellular and  easy to establish.
    Related Articles | Metrics
    Research progress of resveratrol on gynecological tumors
    NI Qin, ZHOU Huai-Jun
    2014, 41 (7):  526-529.  doi: 10.3760/cma.j.issn.1673422X.2014.07.014
    Abstract ( 593 )   PDF (727KB) ( 1526 )   Save
    Resveratrol is one kind of polyphenolic compounds widely existing in grapes and other plants. Recent studies have documented that resveratrol may play antitumor role by mechanisms of antioxidant, cyclooxygenase inhibition, antiproliferation, differentiation and apoptosis in gynecological tumors,such as cervical cancer,ovarian cancer and endometrial carcinoma.
    Related Articles | Metrics
    New applications of apolipoprotein A1 in ovarian cancer
    ZHANG Jun-Jun, SHI Jian
    2014, 41 (7):  529-533.  doi: 10.3760/cma.j.issn.1673422X.2014.07.015
    Abstract ( 544 )   PDF (740KB) ( 1282 )   Save
    Apolipoptotein A1 is the main component of highdensity lipoprotein cholesterol in the plasma, which plays an important role in the lipid transportation and metabolism. It is closely related with cardiovascular disease, liver disease, hereditary amyloidosis and so on. CA125, as an important biomarker, has been widely used for the diagnosis and monitoring treatment of ovarian cancer. Improved sensitivity and specificity of diagnosis are obtained when it is combined with other tumor markers, especially CA125. As reported recently, it also  is related with the generation, progress and prognosis of ovarian cancer. It has been promising to be a new kind of treatment.
    Related Articles | Metrics
    The occurrence,development and metastasis in bone neoplasms
    YANG Cheng, SU Hong-Wei, REN Hui-Wen, LI Hong-Wei
    2014, 41 (7):  533-536.  doi: 10.3760/cma.j.issn.1673422X.2014.07.016
    Abstract ( 448 )   PDF (788KB) ( 1364 )   Save
    Bone tumor is one kind of malignant tumor which threats life among children and adolescent. Osteosarcoma(OS) and Ewing sarcoma(ES) have been paid much attention by medical community because of their complex occurrence, development, metastasis mechanism and poor prognosis. The research showed that activation of protooncogene and mutation of suppressor gene, absence of apoptosis signal and hypoxiainducible factor (HIF) all participated in the occurrence, development and metastasis of OS and ES. It is suggested that clarified pathomechanism of bone tumors could provide more effective therapeutic strategies and lower the mortality of patients.
    Related Articles | Metrics
    Research of aromatase inhibitorassociated arthralgia
    DONG Xin-Yue, FANG Li-Ping, JIANG Kui
    2014, 41 (7):  536-540.  doi: 10.3760/cma.j.issn.1673422X.2014.07.017
    Abstract ( 548 )   PDF (739KB) ( 1497 )   Save
    Aromatase inhibitors (AI) are the leading care for the adjuvant treatment of hormone responsive carcinoma of the breast as  demonstrated in a number of large international phase III randomised trials. Aromatase inhibitorassociated arthralgia(AIA)was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. The pathogenesis of AIA is not very clear currently, with the cause of most research focusing on estrogen deprivation,immune abnormalities,tenosynovial changes and joint effusions. It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA,thereby improving breast cancerrelated outcomes.
    Related Articles | Metrics
    The study on the diagnostic value of serum pepsinogens to gastric precancerous lesions
    ZHANG Jun-Wang, ZHEN Jun-Hong, SHI Shui-Sheng, YU Shan, WANG Shou-Tao, QI Ying
    2014, 41 (7):  541-545.  doi: 10.3760/cma.j.issn.1673422X.2014.07.018
    Abstract ( 373 )   PDF (819KB) ( 1406 )   Save
    ObjectiveTo investigate the possibility and quantitative range of pepsinogen(PG) used as the screening marker of gastric cancer by detecting serum pepsinogen level in different gastric mucous pathologic status. MethodThe level of serum pepsinogenⅠ(PGⅠ) and pepsinogenⅡ(PGⅡ) by time resolved fluoroimmunoassay(TRFIA) in 64 chronic atrophic gastritis patients,63 gastric mucous atypical hyperplasia patients, 67 gastric cancer patients and 20 healthy volunteers were defeeted , and the ratio of PGR(PGⅠ/ PGⅡ) was calculated. Then the three kinds of diseases were graded. The data was analyzed between groups and subgroups. Result①Compared with normal control group, the median PGⅠvalues were 124.01,91.23 and 71.23 respectively, which were all lower than that of healthy group (152.00). There were significant differences(Z=-2.52,P=0.017 0;Z=-3.42,P=0.001 4;Z=-3.57,P=0.000 9).The median PGR values were 7.61,5.21 and 4.32 respectively, which were also lower than that of healthy group, the differences were significant(Z=-2.98,P=0.002 9;Z=-3.17,P=0.000 2;Z=-2.89, P=0.000 1). The PGⅡlevel of these diseases were not significantly different with control group. ②The serum PGⅠlevel of gastric mucous atypical hyperplasia and gastric cancer were reduced significantly in contrast with atrophic gastritis (Z=-3.42,P =0.001 4;Z=-3.62,P=0.000 9); the levels of PGⅡ and PGR were varied without significance(P>0.05); ③The levels of PGⅠamong atrophy gastritis and gastric cancer subgroup have no significant difference(χ2=2.86,P=0.414 3;χ2=1.67,P=0.136 8).But the level of PGⅠwas significantly different in gastric atypical hyperplasia(χ2=0.83,P=0.043 0).It decreased in light and medium grade dysplasia and went up in severe grade dysplasia. The levels of PGⅡ and PGR were varied without significance(P>0.05). ④The areas under the ROC curves performed by the PGⅠ and PGR from normal control group and atypical hyperplasia group were 0.782 and 0.831 respectively; The sensitivity and specificity of PGⅠ≤72.12 μg/L and PGR≤4.32 for gastric dysplasia were 89.48% and 76.31% respectively. Conclusion①The level of PGⅠand PGR were decreased along with the seriousness of gastric pathological changes and probably regarded as the screening markers of gastric mucous malignant transformation.②Serum pepsinogen level is closely correlated with gastric precancerous lesion, PGI≤72.12 μg/L and PGR≤4.32 has better specificity and sensitivity for gastric atypical hyperplasia in this area.
    Related Articles | Metrics
    Pemetrexed in combination with cisplatin in the treatment of advanced breast cancer application
    YUE Li-Juan, HOU Xin-Li, XUE Hui, XUE Ling, GAO Xiang, SHEN Yong, YUAN Liang, ZHANG Jing-Jing, ZHU Hong-Cai
    2014, 41 (7):  545-548.  doi: 10.3760/cma.j.issn.1673422X.2014.07.019
    Abstract ( 642 )   PDF (731KB) ( 1324 )   Save
    ObjectiveTo study recent clinical efficacy and adverse reactions of pemetrexed in combination with cisplatin in the treatment of advanced breast cancer . MethodsUsing envelopes andrandomly the patients were dividing into treatment group and control group. The treatment group with 18 cases of advanced breast cancer were treated with pemetrexed and cisplatin while in the control group , 23 cases advanced breast cancer patients were treated with gemcitabine and cisplatin with 21 days as a cycle. The efficacy and adverse reactions were determined according to the WHO on Response Evaluation Criteria in Solid Tumors therapy and chemotherapy toxicity evaluation criteria. ResultsTumor control rate in the treatment group was 83.3%(15/18),while  in the control group was 78.3%(18/23), and the difference was not statistically significant (χ2=0.000 94,P> 0.05); while the adverse reactions differenced between the treatment group and the control group were statistically significant(bone marrow suppression χ2=9.23;fatigue χ2=4.96;nausea and vomiting χ2=4.98;diarrhea χ2=4.45;skin rash χ2=5.03,P<0.05). ConclusionPemetrexed combined with cisplatin in patients with advanced breast cancer has a good effect, and the adverse reaction is low.
    Related Articles | Metrics
    The diagnostic value of human epididymis protein 4 and carbohydrate  antigen 125 for patients with ovarian neoplasms
    SUN Ting, DU Li-Li, XU Xiao-Qin, WANG Yan, HAN Cun-Zhi, JING Jie-Xian
    2014, 41 (7):  549-553.  doi: 10.3760/cma.j.issn.1673422X.2014.07.020
    Abstract ( 581 )   PDF (731KB) ( 1196 )   Save
    ObjectiveTo evaluate the diagnostic value of human epididymis protein 4(HE4) and carbohydrate antigen 125(CA125) for distinguishing between benign and malignant ovarian neoplasms. Methods1109 patients with ovarian neoplasms were enrolled in this study, serum concentration of HE4 and CA125 was assayed using ELISA technique.And the markers were evaluated for significance separately and in combination. Results1 Serum levels of HE4 and CA125 were significantly higher in postmenopausal women than those in premenopausal women(t=8.40,P<0.05;t=7.02,P<0.05). In addition, the more children the patients born, the higher serum levels of these two markers were(F=15.36,P<0.05;F=13.00,P<0.05). 2 Serum HE4 levels were significantly higher in the ovarian cancer patients compared with those seen in patients with benign or borderline tumor(t=13.68,P<0.05;t=14.94,P<0.05). Serum CA125 levels were significantly higher in the ovarian cancer patients compared with those seen in patients with benign or borderline tumor(t=14.16,P<0.05;t=17.27,P<0.05). Morever, it also appared in the ovarian cancer patients with ascites and vascular embolism. Morever,the levels of HE4 were significantly higher in the ovarian cancer with ascites and vascular embolism than without it(t=7.08,P<0.05;t=4.41,P<0.05),the levels of CA125 were significantly higher in the ovarian cancer with ascites and vascular embolism than without it(t=9.67,P<0.05;t=4.75,P<0.05). 3 During followup, serum HE4 and CA125 levels significantly decreased at 3 months after operation(t=9.86,P<0.05;t=5.12,P<0.05). 4 Receiver operating characteristic curve,ROC) analysis revealed that no difference was observed in AUC values for HE4, CA125 and risk of ovarian malignancy algorithm(ROMA). 5 Compared to CA125, HE4 had significantly higher specificity and lower sensitivity.However,sensitivity were increased when the two markers were combined with each other. However,the sensitivity of combination with two markers was higher than single detection and ROMA,but the specificity was lower in combination with two markers than single detection and ROMA.If we divide the ROMA by a woman′s menopausal status, ROMA has a higher sensitivity(73.84%,84.19%) and lower specificity(66.06%,66.67%). ConclusionsThe levels of CA125 has a high sensitivity, and the levels of HE4 is a high specificity. CA125 combined with HE4 can provide a more sensitivity and accurate predictor of ovarian cancer than either alone.
    Related Articles | Metrics